InMode (NASDAQ:INMD) vs. Haleon (NYSE:HLN) Financial Survey

InMode (NASDAQ:INMD) and Haleon (NYSE:HLN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for InMode and Haleon, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1	5	1	0	2.00
Haleon	1	2	4	2	2.78

InMode currently has a consensus target price of $17.25, indicating a potential upside of 20.55%. Haleon has a consensus target price of $12.33, indicating a potential upside of 33.17%. Given Haleon’s stronger consensus rating and higher possible upside, analysts plainly believe Haleon is more favorable than InMode.

Earnings & Valuation

This table compares InMode and Haleon”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49 million	2.45	$93.83 million	$1.44	9.94
Haleon	$14.54 billion	2.83	$2.20 billion	$0.39	23.73

Haleon has higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares InMode and Haleon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InMode	25.33%	14.52%	12.88%
Haleon	N/A	N/A	N/A

Volatility & Risk

InMode has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Haleon has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.

Insider and Institutional Ownership

68.0% of InMode shares are held by institutional investors. Comparatively, 6.7% of Haleon shares are held by institutional investors. 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Haleon beats InMode on 8 of the 15 factors compared between the two stocks.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.